Journal of International Obstetrics and Gynecology ›› 2020, Vol. 47 ›› Issue (5): 531-535.

Previous Articles     Next Articles

Adjuvant Therapy of Uterine Sarcoma 

FENG Shu-jie,ZHOU Qi-min,HE Ling-ling,LI Rui-yan,YU Xiao-yun,WANG Hai-lin   

  1. The First Clinical Medical College of Lanzhou University,Lanzhou 730000,China(FENG Shu-jie,HE Ling-ling,LI Rui-yan,YU Xiao-yun,WANG Hai-lin);Gansu Provincial Hospital,Lanzhou 730000,China(ZHOU Qi-min,WANG Hai-lin)
  • Received:2020-05-06 Revised:2020-07-14 Published:2020-10-15 Online:2020-10-27
  • Contact: WANG Hai-lin,E-mail:hailinwang2020@163.com E-mail:hailinwang2020@163.com

Abstract: Uterine sarcoma is a rare but aggressive tumor accounting for 3%-7% of all uterine cancers. The disease is insidious and diverse histologically, and no standard treatment has been established. At present, surgical treatment is the preferred treatment, but postoperative recurrence rate is still high,which seriously affects the long-term survival of patients. Therefore, the postoperative adjuvant treatment of uterine sarcoma has become one of the focus of research at home and abroad, but its reliability and effectiveness still have no unified conclusion. In this review, we have summarized current states and latest progress of postoperative adjuvant therapy in common types of uterine sarcoma, especially focusing on the methods of postoperative adjuvant treatment of uterine leiomyosarcoma and low-grade endometrial stromal sarcoma, in order to provide the corresponding treatment ideas for the clinical practice.

Key words: Uterine neoplasms;, Sarcoma;, Leiomyosarcoma;, Sarcoma, endometrial stromal;, Antineoplastic combined chemotherapy protocols;, Uterine sarcoma